

RetinalGeniX™

INVESTOR PRESENTATION

FALL 2025

OTCQB: RTGN

DISCLAIMER

This presentation contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding preventing blindness, the proprietary technologies being developed by the Company to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, the Company’s planned Nasdaq listing, the Company’s geography, facility and medical sector pipeline and the Company’s clinical drug development pipeline. These forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to develop technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this presentation is provided only as of the date of this presentation, and we undertake no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.

Mission

The prevention of blindness and the early detection and treatment of multiple systemic and ocular diseases

"The eyes are the mirror of the soul and reflect everything that seems to be hidden; and like a mirror, they also reflect the person looking into them"[1]

Source: Goodreads.com; Manuscript found in Accra

Company Overview

RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer's disease and Parkinson's disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer's disease/dementia.





Company Offerings: 3 Core Technologies



Proprietary Advanced Hardware

- RetinalCam™ high-resolution real-time retinal and ocular imaging and monitoring connects patients with the proprietary eye-specialty provider network and is available for patient/doctor use 24/7



Genetic Biomarkers and Therapeutics

- Genetic Virtual Test: Non-invasive, cost-effective evaluation of patient's disease risk profile via DNA and RNA biomarkers



RetinalGeniX DNA/RNA/GPS Pharmaco-Genetic Mapping™

- Software to validate and guide the development of novel methods and therapeutic products

Investment Highlights

Remote monitoring device patented to assist in the diagnosis of systemic and ocular disease and prevent blindness
- Soon to be commercialized

$10B market opportunity
(AMD and Alzheimer's alone)[1]

New drug development enhancing the portfolio of drugs and investigating alternative uses

Advancement of early diagnosis and treatment of systemic and ocular diseases AMD, Alzheimer's, cancer, diabetes, heart disease, HIV, hypertension, stroke, etc.

Industry-leading medical and advisory team with 100+ years of experience in the field

Significant demand for the Company's product satisfying huge unmet needs

RetinalGeniX DNA/RNA/GPS virtual test provides a **non-invasive and cost-effective** way to evaluate a patient's disease risk profile

Planned Nasdaq uplisting - raising capital to complete product development; after securing the funds, Company will apply to uplist on Nasdaq

1) Source: Management estimate

Strategic Vision

1. Screen patients more efficiently and effectively via inexpensive and automated retinal mass-screening eye exam devices
2. Increase patient accessibility, healthcare provider availability, and diagnostic efficiency in conducting automated retinal eye exams
3. Allow high-cost eye care specialists greater time to focus on their critical-need patients; as other lesser specialized healthcare providers can now conduct routine screening exams
4. Identify eye and systemic diseases through 24/7 real-time remote monitoring
5. Validate and guide the development of novel methods and therapeutic products through pharmacogenetic mapping and high-resolution imaging

Understanding the Eyes and Bio Markers

Potential Predictor and New Pathway to a Practical & Affordable Diagnosis of Systemic Disease

Eyes

The retina reflects the earliest changes in neuro-degenerative disease, vascular, metabolic, brain functions, and blindness because the eyes are a direct extension of the brain through the optic nerve pathway, which is a direct extension of the brain's white matter.

The eye has similar microscopic tissue as other major organs and is an important part of the larger nervous system, abnormalities found within the blood vessels may signal similar changes that eventually could develop in other parts of the body.



Bio Markers

- A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.[1]
- A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers help us understand relationships between environmental chemicals and human diseases to improve our ability to diagnose, monitor, or predict disease risk.[2]
- The development process encompasses a non-invasive, economical assessment of patient disease risk through DNA and RNA biomarkers, enhancing drug selection, evaluation, and approval processes
- **RNA proteins can predict future diseases years before occurrence**
- **DNA markers are blood markers of current disease**
- **RNA markers are proteins developed by Messenger RNA as a template and expressed as RNA Marker Proteins**
- **The proteins are found in the tears, nasal canal, buccal canal, and blood**

1 Source: National Cancer Institute 2. National Institute of Environmental Health Services

Technology: RetinalGeniX DNA/RNA/GPS Pharmaco-Genetic Mapping™

RetinalGeniX DNA/RNA/GPS Pharmaco-Genetic Mapping™ combined with proprietary patented high-resolution 24/7 real-time retinal imaging technology can enable the detection of the earliest signs of eye and systemic diseases more efficiently and effectively.

> **“Pharmacogenetic mapping revolutionizes drug development.”**
>
> Jerry Katzman, MD
> CEO/Founder

May facilitate the detection of early physiologic changes that may represent biomarkers useful for the detection of blindness or systemic diseases

Only combined platform technology with the ability to screen, monitor, and provide data to profile, identify ocular trends, and create diagnostic markers for systemic and retinal disorders

Software via patient application, bio markers, and drug development

Screens patients more efficiently, effectively, and connects patients with a network of eye-specialty providers

Combined with RetinalCam™ is the basis for therapeutic drug development

Offers initial testing in primary care centers to help prevent expensive scans at labs and hospitals, ultimately improving patients' accessibility and avoiding unnecessary costs

Platform technologies can be used in concert with virtual genetic tests and will be used directly by patients

RetinalCam™: High-Resolution Retinal Examination

RetinalCam™ is a patented real-time monitoring, imaging, and physician alert system device incorporating a high-resolution ocular camera with video streaming capabilities allowing examination of the central 40° of the retina that can detect early signs of retinal and systemic disease without pupil dilation. The device will be affordable, easy-to-use by not only eye care professionals but by all other medical specialties.

Ready for Use and Payments

- Defined CPT codes* for remote monitoring(1)
- Defined codes for retinal digital imaging and/or retinal photography
- Medicare is considering $11 screening payment for diabetes(2)

Target Markets

- *Remote*
- *Health clinics*
- *Emergency rooms*
- *Physician's offices*
- *Mobile health clinics*
- *Telehealth*
- *Pharmacies*
- *Military*
- *Any medical professional site (1,000 of locations)*

In Process

- Patient marketing
- HCP marketing
- Negotiating w/outsourced sales teams
- Vendor contracts TBD
- Prototype near completion

Marketing Plan

- *Patient marketing (Digital/Targeted Campaigns)*
- *Online support/*
- *education groups*
- *HCP marketing*
- *(Digital/targeted, conferences*
- *direct mail, etc.)*
- *Distribution agreements with ophthalmology networks*
- *Physician testing and outreach*

Path to Completion

- ***FDA clearance 510(k) IS NOT REQUIRED for RetinalCam™***
- *Projecting the device to complete testing by Q4 2025*

1)Source: AMA-ASSN.ORG;(CPT®) codes offer doctors and health care professionals a uniform language for coding medical services and procedures to streamline reporting and increase accuracy and efficiency.
2)Source: MedCity News; Medicare prices AI-based screening for diabetic retinopathy Nov. 9, 2021.

RetinalCam™ and Virtual Genetic Tests

Many patients are considered at high risk for loss of sight and blindness. Immediate intervention is needed in various disorders such as diabetic retinopathy, diabetic macular edema, age-related macular degeneration (wet and dry), neurologic disorders, optic neuritis, hemorrhage, stroke vascular disorders, cancer, and other pathologies.

RetinalCam™ Role

- The technology costs far less than expensive diagnostic methods such as MRI, CT and PET scans, ultrasound, echocardiogram, blood draws at specialty labs, retinal testing, and others
- 24/7 real-time physician and patient alert high-resolution retinal imaging, including an external ocular photo system for remote monitoring
- Once identified by their physician, continuous remote monitoring becomes possible and sight-saving. RetinalCam™ can be used by anyone in addition to patients identified by specialty physicians

DNA/RNA GPS Role:

- A non-invasive, cost-effective evaluation of patient's disease risk profile via DNA and RNA biomarkers
- May facilitate the detection of early biomarkers that could be preventative of possible future blindness or systemic disease
- Virtual Genetic Testing via major national Laboratory
- The patient can update the database via the app, which includes current medical diagnosis, medications, illnesses, allergies, diet, and lifestyle
- Medical history software application (in development)



RetinalCam™ Monitoring: How it Works

RetinalGeniX



Drug Therapeutics: Pioneering discovery and solutions for Systemic and Ocular Degenerative Disorders

RetinalGenix is expanding its reach into diagnostics and therapeutics and plans to use its pharmacogenetic mapping RetinalGeniX DNA-GPS™ and high-resolution imaging RetinalCam™ to validate and guide the development of novel methods and therapeutic products.

Company has 2 drug repositioning therapies in development:

- **RTG 2023: for the treatment of Age Related Macular Degeneration (Dry) (PRE IND; Provisional Patent Submitted November 2023 and passed toxicity study)**

- **RTG 2024: for the treatment of some forms of dementia including Alzheimer's (PRE IND; Provisional Patent Submitted November 2023 and passed toxicity study)**

The pharmacogenetic mapping solution could aid in the development and reassignment of existing drug therapies that may be successful in treating alternate but genetically matched systemic diseases.

- **Drug Safety** - Enhanced process to diagnose and monitor a patient's health through high-resolution retinal imaging and genetic mapping
- **Drug Validation** - Allows various targeted drug therapies (old and new) to be developed and/or reinvestigated for their new intended best use
- **Drug Efficacy** - High-resolution retinal imaging can validate biomarkers - Correlation with drug therapeutics can document drug efficacy – Irrelevant retinal image markers can be removed to corroborate drug efficacy

"Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well-accessed and approved by regulatory authorities"(1)

RESULT: Better drug selection, analysis, and validation

1)Low, Z. Y., Farouk, I. A., & Lal, S. K. (2020). Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. Viruses, 12(9). https://doi.org/10.3390/v12091058.

Market Opportunity: Alzheimer's

7TH LEADING CAUSE OF DEATH IN THE UNITED STATES[1]

In 2023, Alzheimer's and other dementias will cost the nation $345B - not including the value of unpaid caregiving

Medicare Total payments for health care, long-term care, and hospice care for people living with dementia are projected to increase to nearly $1 trillion in 2050[4]

$7.7B in 2022

$13.7B by 2030



North American Alzheimer's Therapeutics Estimated Market Size[2]

Over 55 million

People Worldwide Living With Dementia in 2020
Reaching 78 million in 2023 and 139 million by 2050[3]

6.7 million in 2022

139 Million by 2050

Cases in the United States [1,4]

1)NIH.GOV; Alzheimers disease fact sheet.
2)Insights10.com; North America alzheimers disease drugs market analysis.
3)ALZINT.ORG; Dementia facts figures dementia statistics.
4)Ibid.

Market Opportunity: Age-Related Macular Degeneration (AMD)

$9.9B in 2021

$18.3B by 2023

Global Age-Related Macular Degeneration Estimated Market Size(1)

$4.9B

North American Share ~51% of Global Market Estimated Market Size in 2021[2]

~300M

200 million people worldwide are estimated to have AMD as of 2022, and by 2024, this number is projected to be ~300 million[3]

20 million

Cases of AMD in the US: 2 million Wet and 18 million Dry Wet "Advanced Form" Estimated to Double Over The Next 20 Years[4][5]

1)Source: Global Age-Related Macular Degeneration Market Forecast Report by Disease Type, Product Distribution Channel, Countries, and Company Analysis, 2024-2032
2)Source: Ibid.
3)Source: Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy Genes Dis. 2022;9:62–79.
4)Source: CDC.gov; Prevalence of age-related macular degeneration (AMD).
5)Source: AAO.ORG Age-related macular degeneration AMD genetics.

Addressable Market: Healthcare Shortfalls

RetinalGeniX

Early Detection of Systemic Diseases

- 6 in 10 adults in the US have a chronic disease(1)
- The leading causes of death and disability and leading drivers of $4.1 trillion in annual health care costs(1)
- Lack of cost-efficient and easy-to-operate high-resolution screening technology enabling early diagnosis(9)
- Inefficient, requiring the patient to access specialty centers and approvals away from home Sophisticated technicians needed to implement MRI, CT, PET scan, ultrasound, echocardiogram, blood draws at specialty labs, retinal testing, etc.
- Results of diagnoses generally are not immediate or confidential
- Diagnostic equipment is based at universities, large clinics, and hospitals
- Geographic accessibility (Rural even more limited)

Worsening Doctor-to-Patient Ratio

- Delay in early treatment of eye and systemic diseases
- There will be physician workforce shortages throughout the country in 2030(2)
- Specialists needed to interpret test results
- Inefficient, limited, and costly use of eyecare specialists
- Staffing shortages: COVID-19 pandemic brought severe dislocation in the healthcare workforce, which was already facing provider and nursing shortages in many geographies(3)
- Decreasing medical professional population. The US faces a projected shortage of between 37,800 and 124,000 physicians within 12 years(4)
- 30+ million people in the US are without health insurance(5)
- Worldwide, 4.5 billion people were not fully covered by essential health services(6)



Escalating Blindness/Ocular Disease

- Escalating blindness due to maculopathy, age-related macular degeneration (wet and dry), diabetic retinopathy and other eye diseases
- Insufficient number of ophthalmologists and optometrists worldwide <600,000(7)(8)
- Lack of early detection of central visual loss or changes due to therapeutic toxicity and various other causes
- Drug toxicity from many sources, including therapeutics, metabolic and infectious diseases, auto-immune and vascular disorders

1)Source: Center for Disease Control and Prevention; Chronic Diseases in America. May 8, 2023.
2)Source: Zhang, X., Lin, D., Pforsich, H., & Lin, V. W. (2020). Physician workforce in the United States of America: Forecasting nationwide shortages.
3)Source: Pitchbook; Healthcare Services Report Nov. 7, 2023.
4)Source: AMA-ASSN Doctor shortages are here—and they'll get worse if we don't act fast. Apr. 2022.
5)Source: Statista; Americans without health insurance – statistics & facts. Aug. 2023.
6)Source: WHO; Universal Health Coverage Fact Sheet. Oct. 2023.
7)Source: NIH PubMed; Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs?
8)Source: The International Agency for the Prevention of Blindness (IAPB); Mapping the global optometry workforce July 20, 2021.
9)Source: Management Estimate.

Leveraging Current Healthcare Networks

9,284,210

National estimates for U.S. Healthcare Practitioners and Technical Occupations[1]



Worldwide estimates of 232,866 ophthalmologists in 194 countries and an estimated 331,743 optometrists in123 countries [2,3]

1) Source:U.S bureau and labor statistics
2) Source: Statista; eye care professionals in the us forecast 2014 and 2020.
3) Source: IAPB.ORG; mapping the global optometry workforce.

Timeline: Tracking Key Milestones

2017

- *3 Patent awards Visualization of Eye Anatomy*
- *4 trademarks for RetinalGeniX including DNA/GPS, RNA/GPS*

2019

- *Opened HQ and lab*
- *6 ophthalmic medical advisors added*
- *Contract manufacturing agreement (ADM Tronics)*
- *Added ophthalmic engineering team*

2020

- *Doubled ophthalmic engineering team*

2021

- *Obtained license agreement for retinal technologies*
- *Filed S-1 (OTC:RTGN)*

2022

- *Listed on the OTCQB market*
- *Added Dr. Perich to the medical advisory board*
- *Acquired DNA/GPS Inc*
- *Added Vinay Mehindru, MD, MBA to the board of directors*

2023

- *Patent granted for Patient Home Monitoring and Physician Alert System for Ocular Anatomy*
- *Filed 2 preliminary patents for drugs RGT 2023 and RGT 2024*
- *Added Interim CFO Virender Ahluwalia*
- *CRO hired Avania*
- *Added Fred Chasalow Ph.D. therapeutic drug selection and development*
- *Added Herbert Gould, MD to oversee contact lens development*
- *Added Dessy Boneva MD, FACS to BOD*
- *IRB process approved*

2024-2025

- *Planned NASDAQ Uplisting*
- *Commercialization*
- *Ongoing Clinical trials*

RTG 2023: Prophylactic Treatment of Dry AMD

Dry AMD with Drusen
Photo Credit: Lawrence A. Yannuzzi, MD

Drug candidate RTG 2023 is in development to treat the primary stage dry age-related macular degeneration (AMD). Dry AMD can progress to the wet type if not monitored closely by a doctor, it is the leading cause of permanent central vision loss

The study aims to offer recommendations for enhancing the preselection process and management of ocular injections. It is being conducted with a cohort of 110 patients treated via Anti-VEGF therapy requiring ocular injections

Currently, there are **no FDA-approved drugs** to prophylactically treat, stop, or prevent the dry form of this eye disease from progressing to the wet form or treat the wet form, except through intraocular injections[1]. These direct injections into the eyes are a heavy burden on the patient, both financially and emotionally, and must be administered monthly for the rest of their life

1) Source: MACULARSOCIETY.ORG; dry age-related macular degeneration

IRB[1] Clinical Trial: AMD Anti-VEGF

The current pre-IND study aims to offer recommendations for enhancing the preselection process and management of ocular injections

It is being conducted with a cohort of 110 patients currently being treated via Anti-VEGF therapy requiring ocular injections

The proposed patient selection process has the potential to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections. These factors represent significant challenges associated with wet macular degeneration-related vision loss

RetinalGenix regulatory has FDA registered IRB

1) Institutional Review Board Institutional review boards (IRBs) or research ethics committees provide a core protection for human research participants through advance and periodic independent review of the ethical acceptability of proposals for human research.

RTG 2024: Advancing Alzheimer's Treatment Strategies



The provisional patent RTG 2024 focuses on targeting the root causes of **Alzheimer's** at a molecular and cellular level. Unlike the seven existing FDA-approved treatments, that do not affect the underlying brain changes[1], this novel therapeutic approach is designed to interact with the biological pathways directly involved in the disease's progression. Through the modification of these pathways, RTG 2024 seeks to alleviate symptoms, **slow or halt the progression, and treat the root cause** of Alzheimer's

RTG 2024 represents a significant stride in addressing the profound challenge posed by Alzheimer's disease. Alzheimer's, as the most common form of dementia, accounts for 60–70% of dementia cases globally, with an estimated **6.7 million cases** in the U.S. alone as of 2022, scaling to 139 million by 2050, underscoring the urgency for more effective treatments

The economic impact of Alzheimer's and related dementia is projected to soar to nearly $1 trillion by 2050 in Medicare payments alone. RTG 2024 could provide substantial relief to millions of patients and their caregivers, helping to alleviate the immense financial strain on healthcare systems. The approach intends to validate candidates via patient monitoring, potentially changing the trajectory of dementia care via high-resolution imaging validation and corroboration

1) Source: ALZ.ROG; alzheimers facts and figures.pdf.

Contract Research Organization: Avania

AVANIA
ADVANCING YOUR MEDICAL TECHNOLOGY

Avania is an integrated global, full-service CRO with specialized expertise in medical technology. Their end-to-end service model, complete with strategic consulting & product development; data analytics, safety, and compliance; clinical operations; and market access & reimbursement solutions, advances products from concept to commercialization.

Avania is our Contract Research Organization. They are one of the leading global providers of outsourced clinical trial services specifically focused on medical technology. We have hired them to guide us through our FDA interactions including clinical drug trials and medical device development.

Provides active guidance for RetinalGeniX in interactions with the FDA for the development of:

- **RetinalCam™** High-resolution retinal and eye imaging device
- **RTG 2023:** Clinical drug formulation for the treatment of **dry age-related macular degeneration (dry AMD)**
- **RTG 2024:** Clinical drug formulation for the treatment of **Alzheimer's and dementia**

Unrivaled Innovation in Retinal Imaging Solutions

All in USD ($)

Sources: Company websites and Medical Advisory Board sales inquiries.

	RetinalGeniX	optos	TOPCON	ZEISS	NIDEK	Canon CANON MEDICAL	icare
In-Home and Out-of Home Monitoring, 24/7 Real-time Auto-Alert to Physicians Office and Home	✓	X	X	X	X	X	X
Simultaneous Internal and External Imaging	✓	X	X	X	X	X	X
Patient Operated (No Technician Needed)	✓	X	X	X	X	X	X
Voice Activated Operation to Conduct Monitoring	✓	X	X	X	X	X	X
Physician Referral Network	✓	X	X	X	X	X	X
Embedded Patient Data Directory	✓	X	X	X	X	X	X
Easily Portable for Home Monitoring Use	✓	X	X	X	X	X	X
High-Resolution External Imaging Standard	✓	X	X	X	X	X	Requires Technician
High-Resolution Retinal Imaging Standard	✓	✓	✓	✓	✓	✓	✓
Price Range	**<$30k**	**$85k**	**$30-100k**	**$80-90k**	**$30k**	**<$20k**	**$75k**
Auto-Compensation (No Corrective Lens Needed)	✓	✓	✓	✓	✓	✓	✓
No Dilation Needed	✓	✓	✓	✓	✓	✓	✓

Company Snapshot

Market Cap: $36.3 million (1)
Price per Share: $2.01 (2)
Capital Raised: approx. $7.5 million (3)

- **14 Patents Granted**
- **4 Trademarks**
- **2 Drugs** (in development)

1) As of 3/10/2025
2) As of 3/10/2025
3) As of 3/10/2025

Partnerships

ADM Tronics unlimited inc.
AVANIA ADVANCING YOUR MEDICAL TECHNOLOGY
illumina
B | RILEY Financial
USF Health
EISNERAMPER
BLANKROME

Experienced Management



Jerry Katzman, MD

Chairman, President & CEO

- Eye MD surgeon 25+ years and performed the most advanced surgical procedures and techniques used in cataract and refractive surgery and a myriad of general ophthalmology procedures
- Co-Founder President, BOD - EyeCare International. The largest national discount vision network with over 13,000 locations. Expanded to include optometry, audiology, pharmacy, and chiropractic medicine
- CEO and President of Clinical Control Systems, Inc
- Chief Medical Officer and BOD - Amacore Group, Inc
- BS Biomedical Engineering, Boston University, M.D. degree Universidad de Guadalajara, Internal Medicine and residency in Ophthalmology at the Albert Einstein College (Bronx Lebanon Hospital Center)

Stephen Tannenbaum

Business Advisor

- Advised companies and closed transactions across a spectrum of industries, including infrastructure, TMT, healthcare, SPACs, pharmaceuticals, cannabis, and more on strategic and financial opportunities, including M&A, equity, debt capital markets, IPOs, and SPACs
- Unique specialization in pharmaceuticals and cannabis, taking part in raising over $1.5B for businesses in a rapidly changing industry
- Accomplished performance history in capital markets transactions for public and private companies in special situations, working closely in story-driven capital raises, leveraging resources and knowledge to provide thoughtful and actionable advice
- Graduated with a BS in Economics from The Wharton School of The University of Pennsylvania with honors

Seasoned Board of Directors

RetinalGeniX

Jerry Katzman, MD

Chairman, President & CEO

- Eye MD surgeon 25+ years and performed the most advanced surgical procedures and techniques used in cataract and refractive surgery and a myriad of general ophthalmology procedures
- Co-Founder President, BOD - EyeCare International. The largest national discount vision network with over 13,000 locations. Expanded to include optometry, audiology, pharmacy, and chiropractic medicine
- CEO and President of Clinical Control Systems, Inc
- Chief Medical Officer and BOD - Amacore Group, Inc
- BS Biomedical Engineering, Boston University, M.D. degree Universidad de Guadalajara, Internal Medicine and residency in Ophthalmology at the Albert Einstein College

Herbert Gould, MD FACS

Director, Contact Lens Authority and Therapeutics Advisor

- Co-founder - Contact Lens Society of Ophthalmologists ECLA/CLAO and the New York Intraocular Lens Implant Society
- Founding member of:
  - American Intraocular Lens Implant Society
  - International Society of Refractive Surgery
  - New York Keratorefractive Society
- The "flush-fitting shell" designed by Frederick Ridley was introduced to the US by Dr. Gould representing the first use of the term "therapeutic contact lens"
- Made an historic impact on the development and success of various contact lenses
- Implanted the first intraocular lens in China
- Clinical professor and Teaching Fellow in Ophthalmology

Vinay Mehindru, MD MBA

Director

- 25+ years experience in population health, financial performance management, and physician performance enhancement
- President, AdventHealth Physician Network, Tampa Bay & Ocala
- Chief Medical Officer at AdventHealth, Waterman
- Residencies: Internal Medicine Cleveland Clinic & Emergency Medicine University of Florida
- Executive MBA with honors from the University of Texas

Dessy Boneva, MD FACS

Director

- Surgery Clerkship Director at Nova Southeastern University
- Experienced surgeon and Core Faculty in the higher education industry
- Trained at University of Maryland, Dartmouth, Johns Hopkins, and Shock Trauma
- Skilled in Trauma, Surgical Critical Care, Emergency Surgery, Acute Care Surgery, Healthcare Consulting, Advanced Trauma Life Support (ATLS), Prevention and Teaching

World Renowned Medical Advisory

RetinalGeniX

Fred Chasalow, PhD

Special & Therapeutics Advisor

Dr. Chasalow earned his Ph.D. in biochemistry at Brandeis University and served as a post-doctoral fellow at ALZA, then as a Senior Research Associate at Columbia P&S (now Vagelos College of Physicians and Surgeons.) From 1977 to 1995, Dr. Chasalow served at several academic appointments, culminating as Professor of Pediatrics at SUNY, Brooklyn, and Chief of Pediatric Research at Maimonides Medical Center and Director of its Pediatric Endocrine Laboratory. During this period, much of his research included establishing diagnostic methods appropriate for small samples available from infants

In 1991, Dr. Chasalow was appointed as a member of the SuperGen Scientific Advisory Board and played a key role in their scientific development, leading to a successful IPO in 1996. His business experience includes some time as an Associate Vice President at Morgan Stanley and 15 years as an independent financial advisor. In 1995, Dr. Chasalow was one of the founders of AMUR Research. It was in his capacity as Chief Scientific Officer that Dr. Chasalow started the investigation that led to the discovery of three novel steroids. Later, AMUR was sold to SuperGen. Dr. Chasalow founded IOMA LLC which discovered spiral steroids in 2018



Anatoly Dritschilo, MD

Senior Advisor Pharmaco-Genetics

Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc. Formerly, as an educator and translational scientist, he was employed at the Georgetown University and the MedStar Georgetown University Hospital as a radiation oncologist and chairman of the Department of Radiation Medicine. Over a 40+ year career, he has provided clinical services to thousands of patients presenting with cancers of the breast, prostate, and central nervous system. As a translational scientist, Dr. Dritschilo has focused his research on sensitizing cancers to ionizing radiation. He is a leader in the development of antisense oligonucleotides and small molecules directed at targets for radiation sensitization. He has served as Medical Director of Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005 to 2007. He has been a member of the Boards of Directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital, and the MedStar Research Institute. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, his medical degree from the College of Medicine of New Jersey, and residency training from the Harvard Joint Center for Radiation Therapy

Marguerite B. McDonald, MD, FACS

Special Consultant
Device Development & Therapeutics Advisor

Dr. McDonald is a Clinical Professor of Ophthalmology at NYU Langone Medical Center NYC, an Adjunct Clinical Professor of Ophthalmology at Tulane University Health Sciences Center, and a provider at Ophthalmic Consultants of Long Island

Dr. McDonald's ophthalmologic work is celebrated particularly as she performed one of the first laser corrections of the human eye in 1994. She is globally recognized as an authority in laser refractive procedures and ocular surface disease

She has given nearly 600 presentations worldwide and published chapters in over 80 textbooks. Dr. McDonald graduated from Vagelos College of Physicians and Surgeons at Columbia University



Larry Perich, DO

Director of DNA/RNA GPS™ Program and Therapeutics Advisor

Dr. Perich is a Board board-certified ophthalmologist and has been in practice for over 39 years. He developed one of the first laser refractive centers in the Southeast US and founded 3 ambulatory surgery centers

The Perich Eye Centers are one of Florida's largest providers of Medicare Advantage plans providing eye care for over 120,000 patients annually. He is the Program Director for an ophthalmology residency for HCA/USF Bayonet Point, where he has been training residents for over 8 years

He is recognized internationally as a leader in excimer laser surgery and has performed over 75,000 cataract surgeries. He excels in corneal transplants, glaucoma, and cosmetic surgical procedures

Dr. Perich graduated Cum Laude from the University of Southern California, majoring in Biochemistry

World Renowned Medical Advisory

Jack M. Dodick, MD, FACS

Medical Advisor

Dr. Dodick is a world-renowned eye surgeon who has devoted his professional life to teaching, innovation, and patient care. He was a pioneer in the use of intraocular lens implants following cataract surgery and performed eye surgery to teach his techniques in over 20 countries training hundreds of eye surgeons.

His innovations include several surgical instruments and was the first to publish on a laser-based technology to remove human cataracts which he invented, developed, and received marketing approval from the FDA. He has participated in several clinical trials of devices and drugs.

He is currently a Professor and formerly, Chairman, of the Department of Ophthalmology, at the New York University School of Medicine, one of the largest eye residency training programs in the US. He served as Chairman, of the Department of Ophthalmology at the Manhattan, Eye, Ear and Throat Hospital in New York for over 20 years and is a past president of the American Society of Cataract and Refractive Surgery. He previously served as President of numerous other Ophthalmological Societies.

Dr. Dodick is the author of several publications and book chapters on cataract and implant surgery and has presented hundreds of lectures on the subject worldwide.

Ahmed Mohiuddin, MD, MACC

Medical Advisor

Dr. Mohiuddin is an internationally renowned cardiologist. As an early adopter of telemedicine, he established programs in India and Dubai and has been an advisor to several governments around the world.

He has held many positions, including Chairman and CEO of the New England Heart Center and President of its foundation, Chairman and President of the Medical Center of Boston International, and Chairman and Chief Emeritus of Cardiology at the New England Baptist Hospital Boston and has been a member of numerous councils at Harvard University.

Dr. Mohiuddin is a Diplomate American Board of Internal Medicine, Diplomate American Board of Cardiovascular Diseases, a Fellow of the American College of Cardiology, and is affiliated with Brigham & Women's Hospital & Beth Israel Deaconess Medical Center.

Lawrence A. Yannuzzi, MND

Medical Advisor

Dr. Yannuzzi is recognized as a devoted and excellent educator, a superb clinical diagnostician, and a prolific organizer of retinal meetings worldwide. He has made numerous innovations in imaging, drug development, and therapeutic modalities and was the first to use oral non-steroid anti-inflammatory medication for the treatment of cystoid macular edema having developed an eye drop to treat this condition.

He is the founder of Vitreous Retina Macula New York, vice-chairman and director of the LuEsther T. Mertz Retinal Research Center of the Manhattan Eye, Ear & Throat Hospital, and the founder and president of The Macula Foundation, Inc., distributing several million dollars to eye research across the country
Dr. Yannuzzi has published over 550 scientific papers and 13 books and is the recipient of numerous awards which are too numerous to list here but include the Lifetime Achievement Award by the American Academy of Ophthalmology.

Taimour Langaee, MSPH, PhD

Medical Advisor

Taimour Langaee, MSPH, PhD, a Scientific Advisor at RetinalGeniX currently serves as Professor in the Department of Pharmacotherapeutics and Clinical Research at the University of South Florida's Taneja College of Pharmacy. He has taught several courses and has mentored and supervised many undergraduate students, PharmD candidates, graduate students, postdoctoral fellows, PGY2 Clinical PGx pharmacy residents, medical residents, and junior faculty members. Prior to this, Dr. Langaee was a leading figure at the University of Florida, where he directed the Center for Pharmacogenomics and Precision Medicine Genotyping Core Laboratory and contributed to numerous NIH-funded projects focused on the genetic determinants of drug response and personalized medicine.

He has led and collaborated on major research initiatives throughout his distinguished career, including the NIH Warfarin Study (COAG Trial), the Personalized Medicine Program, and multiple pharmacogenomic studies in cardiovascular, infectious, and neurological diseases. His work has directly influenced the implementation of pharmacogenetics in clinical practice, improving drug safety and efficacy for diverse patient populations.

Summary and Strategic Outlook

Proprietary technology RetinalGeniX DNA/RNA/GPS Pharmaco-Genetic Mapping™ & **high-resolution retinal imaging RetinalCam™**

RetinalGeniX DNA/RNA/GPS laboratory virtual genetic test kits provide a **non-invasive and cost-effective way to evaluate a patient's disease risk profile**

Only patient-operated, 24/7 patented remote monitoring imaging system **to aid diagnosis of systemic disease and prevent blindness**

Industry-leading medical and advisory team with 100+ years of experience in the field

$10B market opportunity (AMD and Alzheimer's alone)1

Significant demand for the Company's product satisfying huge unmet needs

RetinalGenix is **positioned to become a leader in precision medicine** and **potentially help improve patient outcomes** across multiple disease areas

Raising capital to complete product development; after securing the funds, Company will apply to uplist on Nasdaq

Planning to commercial RetinalCam™ in the coming months

- **Planned uplist to Nasdaq**

1) Source: Management estimate

Thank You

Investor Relations
800-331-5446
ir@retinalgenix.com